Oberweis Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Oberweis Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$19.3M	Buy	780,570 +193,600	+33%	+$4.61M	0.57%	65
2025 Q4	$13.7M	Buy	586,970 +58,410	+11%	+$1.3M	0.5%	79
2025 Q3	$10.4M	Buy	528,560 +60,360	+13%	+$1.24M	0.4%	95
2025 Q2	$10.2M	Buy	468,200 +600	+0.1%	+$14.2K	0.44%	83
2025 Q1	$11.3M	Buy	467,600 +500	+0.1%	+$11.3K	0.57%	65
2024 Q4	$9.75M	Buy	467,100 +8,700	+2%	+$187K	0.46%	82
2024 Q3	$9.11M	Hold	458,400	–	–	0.47%	86
2024 Q2	$7.1M	Hold	458,400	–	–	0.44%	88
2024 Q1	$7.31M	Buy	458,400 +109,800	+31%	+$1.65M	0.53%	74
2023 Q4	$5.86M	Buy	348,600 +55,000	+19%	+$752K	0.55%	68
2023 Q3	$3.43M	Buy	293,600 +110,200	+60%	+$1.47M	0.36%	108
2023 Q2	$2.46M	Buy	183,400 +36,000	+24%	+$518K	0.3%	120
2023 Q1	$2.44M	Buy	147,400 +50,800	+53%	+$838K	0.38%	88
2022 Q4	$1.8M	Buy	+96,600	New	+$1.49M	0.38%	81

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Oberweis Asset Management's CPRX Position: Q1 2026 in Review

Oberweis Asset Management increased its Catalyst Pharmaceutical (CPRX) stake by 33% in Q1 2026, buying an estimated $4.61M and bringing the position to 780,570 shares worth $19.3M. The position accounts for 0.57% of the portfolio, ranked #65.

Oberweis Asset Management first reported a position in CPRX in Q4 2022 and has held it in 14 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

Oberweis Asset Management held 780,570 shares of Catalyst Pharmaceutical worth $19.3M as of Q1 2026.
Oberweis Asset Management bought 193,600 Catalyst Pharmaceutical shares in Q1 2026, an estimated $4.61M.
Catalyst Pharmaceutical made up 0.57% of Oberweis Asset Management's portfolio in Q1 2026, its #65 holding.
Oberweis Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 14 quarters since.
380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Oberweis Asset Management's 13F filing for Q1 2026, filed 15 May 2026.